Hargreaves Bradley S.

This profile gathers the share dealings of Hargreaves Bradley S. in Cell MedX Corp. We count 37 filings; the first trade dates from 1 June 2020 and the latest from 25 August 2022.

Both buying and selling appear: 1 purchase worth €1,350, against 33 sales worth €126k. Netting one side against the other leaves €124k of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 1 option exercise. In 2022 alone, the filings show no purchases and 5 sales.

The record was last updated on 30 August 2022 with an open-market sale (€692) in Cell MedX Corp. The clock since the last published purchase (24 November 2021) now reads 1,795 days. The median gap between a trade and its publication by SEDI is 3 days. That lag is the time during which only the insider knows about the trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEDI disclosures alone and does not predict where the share price will go.